Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome - Institut Paoli-Calmettes
Journal Articles Lung Cancer Year : 2022

Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome

Maryam Karimi
Nicolas Girard
  • Function : Author
Julien Mazieres
Marta Jimenez
  • Function : Author
Sabrina Yara
  • Function : Author
Ivan Bieche

Abstract

Lung cancer remains the most frequent cause of brain metastases (BMs) and is responsible for high morbidity and mortality. Intracranial response to systemic treatments is inconsistent due to several mechanisms: genomic heterogeneity, blood-tumor barrier, and the brain-specific microenvironment. We conducted a study using data from the SAFIR02-LUNG trial. The primary objective was to compare the molecular profiles of non-small-cell lung cancer (NSCLC) with or without BMs. The secondary objective was to explore central nervous system (CNS) outcomes with various maintenance treatment regimens.
Fichier principal
Vignette du fichier
S0169500222004330.pdf (883.52 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03925563 , version 1 (22-07-2024)

Licence

Identifiers

Cite

Alice Mogenet, Fabrice Barlesi, Benjamin Besse, Stefan Michiels, Maryam Karimi, et al.. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. Lung Cancer, 2022, 169, pp.31-39. ⟨10.1016/j.lungcan.2022.05.004⟩. ⟨hal-03925563⟩
280 View
28 Download

Altmetric

Share

More